Riferimento farmaci
Sibeprenlimab
Sibeprenlimab is a medicine in the class miscellaneous. It is used for nephropathy.
- Classe del farmaco: Miscellaneous
- Indicato per: nephropathy
Ultimo aggiornamento Fonti: US FDA label
Per operatori sanitari — solo a scopo di riferimento. Questa pagina è una sintesi breve, non è un parere medico e non sostituisce il RCP ufficiale né il giudizio clinico. Verificare sempre prima di prescrivere o dispensare.
Il contenuto clinico di questa pagina è disponibile solo in inglese.
In breve
- Classe del farmaco
- Miscellaneous
- Forme farmaceutiche comuni
- iniezione
- Dosaggi comuni
- 200 mg/ml
- Nomi commerciali
- 1
- Paesi e mercati
- 1
Per cosa si usa
Come agisce
Binds APRIL with a KD of 0.95 pM, blocking signaling at BCMA and TACI receptors. Inhibiting APRIL reduces serum galactose-deficient IgA1 (Gd-IgA1), which is implicated in the pathogenesis of IgAN.
Dose abituale nell'adulto (sintesi del foglio illustrativo)
Primary IgA nephropathy at risk for progression (reduce proteinuria): 400 mg, subcutaneous injection, once every 4 weeks
Gravidanza e allattamento
- Gravidanza
- Unknown No human data. Monoclonal antibodies cross the placenta, mostly in the second and third trimesters. A monkey ePPND study showed no adverse embryofetal or postnatal effects at about 10-times clinical exposure.
- Allattamento
- Unknown No data on presence in human milk or effects on the infant or milk production. Weigh the benefits of breastfeeding against the mother's clinical need and potential adverse effects on the infant.
Effetti indesiderati segnalati
- Infections
- Injection site reactions
- Upper respiratory tract infection
- Injection site erythema
Controindicazioni
- Serious hypersensitivity to sibeprenlimab-szsi or any excipients.
Chi deve prestare attenzione
- Immunosuppression and increased infection risk: assess for active infection before starting and monitor during treatment. Patients with chronic or recurring infections may be at higher risk of serious infection.
- Limited data with concomitant systemic immunosuppressants; consider the potential for increased immunosuppression.
- Live vaccines are not recommended within 30 days before starting or during treatment; may interfere with vaccine responses.
Informare il farmacista o il medico di gravidanza o allattamento, malattie renali o epatiche, allergie e di ogni altro farmaco o integratore assunto.
Per gli utenti Pro+
Sblocca la pagina completa
Crei un account e avvii una prova di Pro+ per aprire la monografia completa di Sibeprenlimab: dosi, gravidanza e allattamento, effetti indesiderati, avvertenze e tutte le interazioni.
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- How to give it
- Pharmacokinetics
- Patient counselling points
- IV preparation and dilution
Provi Pro+ gratis per 14 giorni sul web. Nessuna carta.
Altri farmaci della stessa classe
Domande frequenti
What is Sibeprenlimab used for?
Sibeprenlimab is a medicine in the class miscellaneous. It is used for Nephropathy.
What side effects have been reported with Sibeprenlimab?
Infections, Injection site reactions, Upper respiratory tract infection, Injection site erythema.
Can Sibeprenlimab be taken in pregnancy or while breastfeeding?
Pregnancy: Unknown. No human data. Monoclonal antibodies cross the placenta, mostly in the second and third trimesters. A monkey ePPND study showed no adverse embryofetal or postnatal effects at about 10-times clinical exposure. Breastfeeding: Unknown. No data on presence in human milk or effects on the infant or milk production. Weigh the benefits of breastfeeding against the mother's clinical need and potential adverse effects on the infant.
What does Sibeprenlimab interact with?
MediHelp does not list a checked interaction for Sibeprenlimab yet. Always tell your pharmacist about every medicine you take.
Monografie complete, posologie e verifica delle interazioni nell'app MediHelp
Apra il riferimento completo, verifichi le interazioni tra più farmaci e usi gli strumenti di posologia nell'app MediHelp.
